Revenue
2023
2024
2025
Lakewood-Amedex Biotherapeutics Inc. (LABT)
Price$1.88Cached quote
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $1.3M | $2.1M | $0 |
| Research & development | $1.3M | $2.1M | $5.5M |
| Operating expenses | $3.8M | $4.0M | $8.6M |
| Operating income | −$3.8M | −$4.0M | −$8.6M |
| Operating margin | −300.52% | −191.45% | — |
| EBITDA | −$3.6M | −$4.7M | −$8.2M |
| EBITDA margin | −288.93% | −224.96% | — |
| Net income | −$3.8M | −$4.9M | −$8.3M |
| Net profit margin | −306.52% | −230.84% | — |
| Basic EPSper basic share | -$2.76 | -$6.94 | -$11.84 |
| Diluted EPSper diluted share | -$2.76 | -$6.94 | -$11.84 |
Owners
Reported shareholders
≈21.58%of listed shares
Ceccacci Peter468.15K shares · Apr 17, 2026
View holders
| Holder | % owned |
|---|---|
Ceccacci Peter | ≈21.58%468.15K shares |
Cooper Kelvin | ≈13.86%300.59K shares |
Balzer Thomas | ≈11.77%255.32K shares |
DeRoma Leonard James | ≈8.65%187.74K shares |
Marex Group Ltd | 2.22%48.17K shares |
HRT FINANCIAL LP | 2.06%44.78K shares |
UBS Group AG | 0.19%4.1K shares |
Tower Research Capital LLC (TRC) | 0.03%624 shares |
OSAIC HOLDINGS, INC. | <0.01%138 shares |
Blue Trust, Inc. | <0.01%11 shares |
Percentages use 2.17M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data